Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicycle Continued Access Protocol (BiCAP) in Advanced Solid Tumors
NCT07681674Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Aug 2026
- Primary completion
- May 2030
- Sponsor
- Bicycle Therapeutics
- Conditions
- solid tumor (advanced stage)
01
Overview
Phase 2, open-label trial of zelenectide pevedotin, BT7480 and nuzefatide pevedotin in solid tumor (advanced stage) (3 arms), sponsored by Bicycle Therapeutics. Primary endpoint: Safety and tolerability up to 48 months. Planned start Aug 2026; status: not yet recruiting.
02
Design
3 arms- Study design
- Non-randomizedOpen-label
Zelenectide pevedotin
Participants will continue on the same treatment regimen they were receiving in their parent study.
BT7480
Participants will continue on the same treatment regimen they were receiving in their parent study.
Nuzefatide pevedotin
Participants will continue on the same treatment regimen they were receiving in their parent study.
03
Who it enrols
Participants must be currently receiving and deriving clinical benefit from a Bicycle investigational product (zelenectide pevedotin, nuzefatide pevedotin, or BT7480) in a parent Bicycle-sponsored study, without disease progression or meeting discontinuation criteria.
04
Endpoints
Primary
Safety and tolerability
Beyond the preview
Go deeper on NCT07681674.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681674.